WO2026120489 - PHARMACEUTICAL COMPOSITIONS OF VOSORITIDE
National phase entry is expected:
Publication Number
WO/2026/120489
Publication Date
11.06.2026
International Application No.
PCT/IB2025/062342
International Filing Date
03.12.2025
Title **
[English]
PHARMACEUTICAL COMPOSITIONS OF VOSORITIDE
[French]
COMPOSITIONS PHARMACEUTIQUES DE VOSORITIDE
Applicants **
RK PHARMA INC
Inventors
KOVI, Ravishanker
PRASAD, Vure
KASU, Raghu Rami Reddy
KANNAPPAN, Jayaraman
SULTANA, Naziya
Priority Data
202441094905
03.12.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
|
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2043 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 2184 | |
| South Korea | Filing, Examination, Granting | 2004 | |
| USA | Filing, Examination, Granting | 7330 |
Total:
25,137
Contact Us
Abstract[English]
The present invention relates to improved Pharmaceutical compositions of Vosoritide The present invention further relates to Pharmaceutical formulation comprising Vosoritide and pharmaceutically acceptable excipients. The present invention further relates to stable formulation of Vosoritide having a purity greater than 99.5% by HPLC.[French]
La présente invention concerne des compositions pharmaceutiques améliorées de vosoritide. La présente invention concerne en outre une formulation pharmaceutique comprenant du vosoritide et des excipients pharmaceutiquement acceptables. La présente invention concerne en outre une formulation stable de vosoritide ayant une pureté supérieure à 99,5 % déterminée par CLHP.